Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jens Mani"'
Autor:
Eva Juengel, Jasmina Makarević, Michael Reiter, Jens Mani, Igor Tsaur, Georg Bartsch, Axel Haferkamp, Roman A. Blaheta
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 4, Pp 291-300 (2014)
Inhibitors of the mammalian target of rapamycin (mTOR) have improved the treatment of renal cell carcinoma (RCC). However, chronic drug exposure may trigger resistance, limiting the utility of these agents. The metastatic behavior of RCC cells, susce
Externí odkaz:
https://doaj.org/article/fff53da712ce4e9790e0809b4b438f46
Autor:
Jasmina Makarević, Jochen Rutz, Eva Juengel, Sebastian Maxeiner, Jens Mani, Stefan Vallo, Igor Tsaur, Frederik Roos, Felix K.-H. Chun, Roman A. Blaheta
Publikováno v:
Cells, Vol 7, Iss 9, p 129 (2018)
This study was designed to investigate whether epigenetic modulation by histone deacetylase (HDAC) inhibition might circumvent resistance towards the mechanistic target of rapamycin (mTOR) inhibitor temsirolimus in a prostate cancer cell model. Paren
Externí odkaz:
https://doaj.org/article/5219719139154a06821f46debcb7b746
Autor:
Jens Mani, Jasmina Makarević, Eva Juengel, Hanns Ackermann, Karen Nelson, Georg Bartsch, Axel Haferkamp, Roman A Blaheta
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e83709 (2013)
Scientists who are members of an editorial board have been accused of preferentially publishing their scientific work in the journal where they serve as editor. Reputation and academic standing do depend on an uninterrupted flow of published scientif
Externí odkaz:
https://doaj.org/article/4fcb0daef0cb435b8d3d0223b79da4e7
Autor:
Jens Mani, Jasmina Makarević, Eva Juengel, Hanns Ackermann, Karen Nelson, Axel Haferkamp, Roman A Blaheta
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e52420 (2012)
The pathophysiologic mechanisms behind urologic disease are increasingly being elucidated. The object of this investigation was to evaluate the publication policies of urologic journals during a period of progressively better understanding and manage
Externí odkaz:
https://doaj.org/article/efbd05dbb22b4ec09073adb4bcefb14a
Publikováno v:
Curr Urol
OBJECTIVES: Although testicular cancer (TC) is the most common tumor in young men in Western countries, there is no official cancer detection/screening program for young men in Germany. The most important TC detection tool is self-examination of the
Publikováno v:
Oncology Research and Treatment. 43:228-236
Aims: The study aimed to evaluate the prevalence of mental distress in patients with newly diagnosed bladder cancer, the cancer-information search behavior, and the influence of information seeking on distress. Methods: One hundred and one bladder ca
Autor:
Christopher Netsch, Jens Mani, Georg Bartsch, Philipp Mandel, Christian Doehn, Anne-Karoline Ebert, Roswitha Siener
Publikováno v:
Uro-News. 23:14-28
Alljahrlich werden auf dem Kongress der Deutschen Gesellschaft fur Urologie (DGU) die neuesten Entwicklungen und Studiendaten vorgestellt. Sieben Experten haben fur ihr jeweiliges Fachgebiet die zentralen Erkenntnisse aus Hamburg zusammengefasst: Was
Publikováno v:
Der Urologe. 58:790-794
Background Early detection of localized testicular cancer is associated with a significantly better prognosis compared to advanced tumor stages. Testicular cancer prevention campaigns like "Hodencheck.de" launched by the German Society of Urology or
Autor:
Kilian M. Gust, Igor Tsaur, Stefan Vallo, Georg Bartsch, Jens Mani, Thomas Höfner, Hendrik Borgmann, Axel Haferkamp, Maximilian Peter Brandt, Eva Herrmann, Christian Thomas
Publikováno v:
Cancer Epidemiology. 52:63-69
Incidence rates for urothelial carcinoma (UC) have been reported to differ between countries within the European Union (EU). Besides occupational exposure to chemicals, other substances such as tobacco and nitrite in groundwater have been identified
Autor:
Jens Neuschäfer, Christian Resch, Eva Juengel, Felix K.-H. Chun, Jochen Rutz, Frederik Roos, Roman A. Blaheta, Sebastian Maxeiner, Jens Mani
Publikováno v:
Nutrition and cancer. 72(3)
The natural compound, amygdalin, is notably popular with prostate cancer patients as an alternative or complementary treatment option. However, knowledge about its mode of action is sparse. We investigated amygdalin's impact on prostate cancer adhesi